EZH2 knockdown or EZH2 inhibitor (DZNep) reduced the levels of EZH2 and H3K27me3 at the ZIC4 promoter region, leading to the upregulation of ZIC4 and a reduction in the proliferation and invasiveness of HCC cells [45]. This evidence concerns the gene EZH2 and hepatocellular carcinoma.